Visão geral da empresa
A biopharmaceutical entity, ANI Pharmaceuticals, Inc. is dedicated to the development, manufacturing, and marketing of a diverse portfolio of branded and generic pharmaceutical products across the United States and international markets. The company operates within the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry, which implies a focus on producing essential medicinal compounds including injectables, softgel capsules, and specialized gel formulations such as Cortrophin. With a total of 970 employees generating annual revenue of $883.37 million, the firm maintains a significant presence in the specialty pharmaceutical landscape. Its market capitalization stands at $1.77 billion, a valuation that reflects the market's assessment of its revenue generation capabilities relative to its operational scale and the competitive dynamics of the healthcare industry.
Saúde financeira
The company reported a total revenue of $883.37 million over the trailing twelve months, resulting in a net income of $70.22 million and an EBITDA of $174.75 million. The substantial difference between the $883.37 million in revenue and the $70.22 million in net income reveals a cost structure where approximately 92% of revenue is consumed by costs of goods sold, operating expenses, and taxes before reaching the bottom line. The company generated free cash flow of $119.42 million, which provides a critical measure of financial flexibility by indicating the cash remaining after accounting for capital expenditures and operating expenses. This positive cash flow suggests the ability to fund operations, service debt, or pursue strategic initiatives without relying solely on external financing. The gross margin stands at 61.4%, indicating a high level of efficiency in production and pricing power before overhead costs are deducted. The operating margin is 12.0%, reflecting the company's ability to control overhead and administrative expenses effectively to convert gross profit into operational profit. The profit margin of 8.9% demonstrates the final percentage of revenue that translates into actual net earnings available to shareholders. In terms of leverage, the company holds $294.72 million in cash against $628.28 million in debt, resulting in a debt-to-equity ratio of 116.19, which characterizes the balance sheet as moderately leveraged given the high ratio. The current ratio is 2.71, indicating a robust short-term liquidity position where current assets significantly exceed current liabilities, ensuring the ability to meet short-term obligations. Return on equity is 16.2%, while return on assets is 3.8%, metrics that reveal the effectiveness of management in generating returns specifically on shareholder equity versus the broader asset base.
Avaliação de valorização
The trailing twelve-month P/E ratio is 23.80, while the forward P/E is significantly lower at 7.51, implying that the market expects a substantial increase in future earnings that is not yet reflected in current price levels. The price-to-book ratio is 3.06, which indicates that the company trades at a significant premium over its book value, suggesting investors are pricing in intangible assets like intellectual property and brand value rather than just tangible assets. Alternative valuation metrics include a price-to-sales ratio of 2.01 and an EV/EBITDA of 11.35, suggesting the company is valued reasonably relative to its sales and earnings power when adjusted for enterprise value. The stock has traded within a 52-week range between a low of $56.71 and a high of $99.50, with the current price position relative to this range determined by the specific market price at the time of analysis. The beta value is 0.43, which indicates that the stock price volatility is significantly lower than the broader market, suggesting less sensitivity to general market fluctuations.
Growth & Income
The company recorded a revenue growth of 29.6% year-over-year, whereas the earnings growth rate is listed as N/A, preventing a direct calculation of whether earnings are growing faster or slower than revenue at this specific moment. The absence of an earnings growth figure alongside the high revenue growth suggests that recent profitability metrics may be volatile or that the expansion is driven primarily by top-line volume rather than immediate margin expansion. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning the firm reinvests all available earnings into research, development, and operational growth rather than returning cash to shareholders. Consequently, the overall growth and income profile is characterized by aggressive top-line expansion without a yield component, relying entirely on capital appreciation potential derived from the high revenue growth rate and the company's ability to sustain profitability as it scales operations.